Protagenic Therapeutics, Inc.\new

Protagenic Therapeutics, Inc. (the “Company”) will not be able to file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 by the prescribed due date without unreasonable effort or expense. The Company is working to complete the remaining items as promptly as practicable but does not expect to file the Form 10-Q within the five-day extension period provided by Rule 12b-25

The Company has been unable to complete its Annual Report on Form 10-K within the prescribed time period without unreasonable effort or expense because additional time is required to complete the audit of its consolidated financial statements and related disclosures. During the fiscal year, the Company entered into a business combination transaction requiring the application of complex accounting guidance, accounting, and related financial reporting considerations. Management and the Company’s independent registered public accounting firm require additional time to complete their evaluation of these matters, finalize the Company’s financial statements, complete required audit procedures, and complete the review of the related disclosures. The Company currently expects to file its Annual Report on Form 10-K within the fifteen-calendar-day extension period permitted under Rule 12b-25. Forward-Looking Statements This Notification of Late Filing on Form 12b-25 contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the Company’s expectation that it will complete its audit and file its Annual Report on Form 10-K within the extension period prescribed by Rule 12b-25 under the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and assumptions that could cause actual results or the timing of events to differ materially from those expressed or implied by such statements

Protagenic Therapeutics, Inc. (the “Company”) will not be able to file its Quarterly Report on Form 10-Q for the period ended December 31, 2025 by the prescribed due date without unreasonable effort or expense. The Company is working to complete the remaining items as promptly as practicable but does not expect to file the Form 10-Q within the five-day extension period provided by Rule 12b-25

Protagenic Therapeutics, Inc. (the “Company”) will not be able to file its Quarterly Report on Form 10-Q for the period ended September 30, 2025 by the prescribed due date without unreasonable effort or expense. The Company expects to file the Form 10-Q within the next few days, and, in any case, within the five-day extension permitted by Rule 12b-25

Protagenic Therapeutics, Inc. (the “Registrant”) has determined that it is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Form 10-K”) by the prescribed due date because of logistical reasons . The Registrant anticipates that it will file the 2021 Form 10-K within the next few days, which will be past its customary timely filing date, and, in any case, on or before the fifteenth calendar day extension provided by Exchange Act Rule 12b-25